Abstract
European countries report large differences in COVID-19 case fatality risk (CFR) and high variation over the year. CFR estimates may both depend on the method used for estimation and of country-specific characteristics. While crude methods simply use cumulative total numbers of cases and deaths, the CFR can be influenced by the demographic characteristics of the cases, case detection rates, time lags between reporting of infections and deaths and infrastructural characteristics, such as healthcare capacities.
We used publicly available weekly data from the national health authorities of Germany, Italy, France and Spain on case and death numbers by age group connected to COVID-19 for the year 2020. We propose to use smoothed data of national weekly test rates for case adjustment and investigated the impact of different time lags from case reporting to death on the estimation of the CFR. Finally, we described the association between case fatality and the demand for hospital beds for COVID-19, taking into account national hospital bed capacities.
Crude CFR estimates differ considerably between the four study countries with end-of-year values of approximately 1.9%, 3.5%, 2.5% and 2.7% for Germany, Italy, France and Spain, respectively. Age-adjustment reduces the differences considerably, resulting in values of 1.61%, 2.4% and 2% for Germany, Italy and Spain, respectively. France’s age-specific data was restricted to hospitalised cases only and is therefore not comparable in that regard. International crude International CFR time series show smaller differences when adjusting for demographics of the cases or the test rates. Curves adjusted for age structure, testing or time lags show smaller variance over the year and a smaller degree of non-stationarity. The data does not suggest any connection of CFRs to hospital capacities for the four countries under study.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
PV, BL and GK received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 101003480 and from the Initiative and Net-working Fund of the Helmholtz Association.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
Data is available on reasonable request.
List of abbreviations
- Overall available hospital beds per 1,000 inhabitants in country j
- CFR
- Case fatality risk
- Age-standardised case fatality risk for country j, in week k
- Lag-adjusted case fatality risk for country j, in week w, with Δ weekly lags
- Test-standardised case fatality risk for age group i, in country j, up to week w
- dijk
- Number of deaths in age group i, in country j, in week k
- d.jk
- Number of deaths over all age groups, in country j, in week k
- Dijw
- Cumulative number of deaths for age group i, in country j, up to week w
- D.jw
- Cumulative number of deaths over all age groups, in country j, up to week w
- Δ
- Lag length
- ECDC
- European Centre for Disease Prevention and Control
- EU
- European Union
- jk,y
- number of hospitalisations per 100,000 inhabitants in country j, from weeks k-γ to k
- i.e.
- id est
- JHU
- Johns Hopkins University
- max{t}
- Global maximum of weekly tests per 100,000 inhabitants
- nijk
- Number of infections in age group i, in country j, in week k
- Nijk
- Cumulative number of infections in age group i, in country j, up to week w
- Cumulative number of observed cases for age group i, country j, up to week w
- Cumulative number of observed cases for over all age groups, country j, up to week w
- Number of observed cases in age group i, in country j, in week k
- Number of observed cases over all age groups, in country j, in week k
- Ñijw
- Cumulative test-adjusted number of cases in age group i, in country j, up to week w
- ñijk
- Test-adjusted number of cases in age group i, in country j, in week k
- ñ*ijk
- Lag-weighted and test-adjusted number of cases in age group i, in country j, in week k
- OECD
- Organisation for Economic Co-operation and Development
- tjk
- Rate of tests per 100,000 inhabitants in country j, in week k
- wi
- Weight of age group i